^
No biomarker
BCC
fluorouracil topical
Sensitive: A1 - Approval
No biomarker
BCC
vismodegib
Sensitive: A1 - Approval
No biomarker
BCC
imiquimod
Sensitive: A1 - Approval
No biomarker
BCC
sonidegib
Sensitive: A1 - Approval
No biomarker
BCC
cemiplimab
Sensitive: A1 - Approval
Sanofi Press Release - 4 weeks
No biomarker
BCC
celecoxib
Resistant: A2 - Guideline
SMO mutation
BCC
vismodegib
Resistant: B - Late Trials
PD-L1 expression
BCC
pembrolizumab
Sensitive: C1 - Off-label
TMB-H
BCC
Immunotherapy
Sensitive: C3 – Early Trials
GLI1 overexpression
BCC
vismodegib
Resistant: C3 – Early Trials
GAS1 underexpression
BCC
vismodegib
Sensitive: C3 – Early Trials
SMO W535L
BCC
sonidegib
Resistant: C4 – Case Studies
SMO Q477E
BCC
sonidegib
Resistant: C4 – Case Studies
SMO D473H
BCC
sonidegib
Resistant: C4 – Case Studies
SMO S533N
BCC
sonidegib
Resistant: C4 – Case Studies
SMO D473G
BCC
sonidegib
Resistant: C4 – Case Studies
PTCH1 1504-1G>T + TMB-H
BCC
nivolumab + vismodegib
Sensitive: C4 – Case Studies